Drug Profile
Zosuquidar - Kanisa Pharmaceuticals
Alternative Names: LY 335979; RS 33295; RS 33295-198; Zosuquidar trihydrochlorideLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Roche
- Developer Kanisa Pharmaceuticals
- Class Alcohols; Antineoplastics; Cyclopropanes; Dibenzocycloheptenes; Piperazines; Quinolines; Small molecules
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 11 Dec 2007 Interim safety and efficacy data from a phase I/II trial in Acute myeloid leukaemia presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)
- 31 Oct 2005 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, In the elderly) in USA (IV)
- 17 Aug 2000 Phase-II clinical trials for Cancer in USA (Unknown route)